GSK plc files 6-K

GSK plc announced that the US FDA has accepted for priority review its New Drug Application (NDA) for bepirovirsen, an investigational treatment for chronic hepatitis B, and has granted it Breakthrough Therapy Designation. The FDA has assigned October 26, 2026, as the PDUFA goal date for this application.